168 related articles for article (PubMed ID: 34769003)
21. Population-based analysis of
Simonin-Wilmer I; Ossio R; Leddin EM; Harland M; Pooley KA; Martil de la Garza MG; Obolenski S; Hewinson J; Wong CC; Iyer V; Taylor JC; Newton-Bishop JA; Bishop DT; Cisneros GA; Iles MM; Adams DJ; Robles-Espinoza CD
J Med Genet; 2023 Jul; 60(7):692-696. PubMed ID: 36539277
[TBL] [Abstract][Full Text] [Related]
22. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.
Ramsay AJ; Quesada V; Foronda M; Conde L; Martínez-Trillos A; Villamor N; Rodríguez D; Kwarciak A; Garabaya C; Gallardo M; López-Guerra M; López-Guillermo A; Puente XS; Blasco MA; Campo E; López-Otín C
Nat Genet; 2013 May; 45(5):526-30. PubMed ID: 23502782
[TBL] [Abstract][Full Text] [Related]
23. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.
Shi J; Yang XR; Ballew B; Rotunno M; Calista D; Fargnoli MC; Ghiorzo P; Bressac-de Paillerets B; Nagore E; Avril MF; Caporaso NE; McMaster ML; Cullen M; Wang Z; Zhang X; ; ; ; Bruno W; Pastorino L; Queirolo P; Banuls-Roca J; Garcia-Casado Z; Vaysse A; Mohamdi H; Riazalhosseini Y; Foglio M; Jouenne F; Hua X; Hyland PL; Yin J; Vallabhaneni H; Chai W; Minghetti P; Pellegrini C; Ravichandran S; Eggermont A; Lathrop M; Peris K; Scarra GB; Landi G; Savage SA; Sampson JN; He J; Yeager M; Goldin LR; Demenais F; Chanock SJ; Tucker MA; Goldstein AM; Liu Y; Landi MT
Nat Genet; 2014 May; 46(5):482-6. PubMed ID: 24686846
[TBL] [Abstract][Full Text] [Related]
24. POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas.
Calvete O; Garcia-Pavia P; Domínguez F; Mosteiro L; Pérez-Cabornero L; Cantalapiedra D; Zorio E; Ramón Y Cajal T; Crespo-Leiro MG; Teulé Á; Lázaro C; Morente MM; Urioste M; Benitez J
J Am Heart Assoc; 2019 Sep; 8(18):e012875. PubMed ID: 31510873
[TBL] [Abstract][Full Text] [Related]
25. MiR-185 targets POT1 to induce telomere dysfunction and cellular senescence.
Li T; Luo Z; Lin S; Li C; Dai S; Wang H; Huang J; Ma W; Songyang Z; Huang Y
Aging (Albany NY); 2020 Jul; 12(14):14791-14807. PubMed ID: 32687062
[TBL] [Abstract][Full Text] [Related]
26. Characterization of POT1 tumor predisposition syndrome: Tumor prevalence in a clinically diverse hereditary cancer cohort.
Herrera-Mullar J; Fulk K; Brannan T; Yussuf A; Polfus L; Richardson ME; Horton C
Genet Med; 2023 Nov; 25(11):100937. PubMed ID: 37466057
[TBL] [Abstract][Full Text] [Related]
27. Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response.
Kim WT; Hennick K; Johnson J; Finnerty B; Choo S; Short SB; Drubin C; Forster R; McMaster ML; Hockemeyer D
EMBO J; 2021 Jun; 40(12):e107346. PubMed ID: 33934394
[TBL] [Abstract][Full Text] [Related]
28. A
Abu Shtaya A; Kedar I; Bazak L; Basel-Salmon L; Barhom SF; Naftali M; Eskin-Schwartz M; Birk OS; Polager-Modan S; Keidar N; Reznick Levi G; Levi Z; Yablonski-Peretz T; Mahamid A; Segol O; Matar R; Bareli Y; Azoulay N; Goldberg Y
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540414
[TBL] [Abstract][Full Text] [Related]
29. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
30. Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer.
Orois A; Badenas C; Reverter JL; López V; Potrony M; Mora M; Halperin I; Oriola J
Horm Cancer; 2020 Apr; 11(2):111-116. PubMed ID: 32172474
[TBL] [Abstract][Full Text] [Related]
31. Role of POT1 in Human Cancer.
Wu Y; Poulos RC; Reddel RR
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987645
[TBL] [Abstract][Full Text] [Related]
32. Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression.
Panero J; Stanganelli C; Arbelbide J; Fantl DB; Kohan D; García Rivello H; Rabinovich GA; Slavutsky I
Blood Cells Mol Dis; 2014; 52(2-3):134-9. PubMed ID: 24239198
[TBL] [Abstract][Full Text] [Related]
33. Germline POT1 mutation and neuroblastoma: A mere coincidence or true association.
Legrand C; Peysselon M; Bidart M; Bouras A
Pediatr Blood Cancer; 2024 Jul; 71(7):e31054. PubMed ID: 38706191
[No Abstract] [Full Text] [Related]
34. G-quadruplex-mediated regulation of telomere binding protein POT1 gene expression.
He Q; Zeng P; Tan JH; Ou TM; Gu LQ; Huang ZS; Li D
Biochim Biophys Acta; 2014 Jul; 1840(7):2222-33. PubMed ID: 24631651
[TBL] [Abstract][Full Text] [Related]
35. RPA and POT1: friends or foes at telomeres?
Flynn RL; Chang S; Zou L
Cell Cycle; 2012 Feb; 11(4):652-7. PubMed ID: 22373525
[TBL] [Abstract][Full Text] [Related]
36. Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.
McMaster ML; Sun C; Landi MT; Savage SA; Rotunno M; Yang XR; Jones K; Vogt A; Hutchinson A; Zhu B; Wang M; Hicks B; Thirunavukarason A; Stewart DR; Koutros S; Goldstein AM; Chanock SJ; Caporaso NE; Tucker MA; Goldin LR; Liu Y
Br J Haematol; 2018 May; 181(3):372-377. PubMed ID: 29693246
[TBL] [Abstract][Full Text] [Related]
37. Heritable defects in telomere and mitotic function selectively predispose to sarcomas.
Ballinger ML; Pattnaik S; Mundra PA; Zaheed M; Rath E; Priestley P; Baber J; Ray-Coquard I; Isambert N; Causeret S; van der Graaf WTA; Puri A; Duffaud F; Le Cesne A; Seddon B; Chandrasekar C; Schiffman JD; Brohl AS; James PA; Kurtz JE; Penel N; Myklebost O; Meza-Zepeda LA; Pickett H; Kansara M; Waddell N; Kondrashova O; Pearson JV; Barbour AP; Li S; Nguyen TL; Fatkin D; Graham RM; Giannoulatou E; Green MJ; Kaplan W; Ravishankar S; Copty J; Powell JE; Cuppen E; van Eijk K; Veldink J; Ahn JH; Kim JE; Randall RL; Tucker K; Judson I; Sarin R; Ludwig T; Genin E; Deleuze JF; ; Haber M; Marshall G; Cairns MJ; Blay JY; ; Thomas DM; Tattersall M; Neuhaus S; Lewis C; Tucker K; Carey-Smith R; Wood D; Porceddu S; Dickinson I; Thorne H; James P; Ray-Coquard I; Blay JY; Cassier P; Le Cesne A; Duffaud F; Penel N; Isambert N; Kurtz JE; Puri A; Sarin R; Ahn JH; Kim JE; Ward I; Judson I; van der Graaf W; Seddon B; Chandrasekar C; Rickar R; Hennig I; Schiffman J; Randall RL; Silvestri A; Zaratzian A; Tayao M; Walwyn K; Niedermayr E; Mang D; Clark R; Thorpe T; MacDonald J; Riddell K; Mar J; Fennelly V; Wicht A; Zielony B; Galligan E; Glavich G; Stoeckert J; Williams L; Djandjgava L; Buettner I; Osinki C; Stephens S; Rogasik M; Bouclier L; Girodet M; Charreton A; Fayet Y; Crasto S; Sandupatla B; Yoon Y; Je N; Thompson L; Fowler T; Johnson B; Petrikova G; Hambridge T; Hutchins A; Bottero D; Scanlon D; Stokes-Denson J; Génin E; Campion D; Dartigues JF; Deleuze JF; Lambert JC; Redon R; Ludwig T; Grenier-Boley B; Letort S; Lindenbaum P; Meyer V; Quenez O; Dina C; Bellenguez C; Le Clézio CC; Giemza J; Chatel S; Férec C; Le Marec H; Letenneur L; Nicolas G; Rouault K
Science; 2023 Jan; 379(6629):253-260. PubMed ID: 36656928
[TBL] [Abstract][Full Text] [Related]
38. Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.
Butler KS; Hines WC; Heaphy CM; Griffith JK
Cancer Med; 2012 Oct; 1(2):165-75. PubMed ID: 23342266
[TBL] [Abstract][Full Text] [Related]
39. CGGBP1 phosphorylation constitutes a telomere-protection signal.
Singh U; Maturi V; Jones RE; Paulsson Y; Baird DM; Westermark B
Cell Cycle; 2014; 13(1):96-105. PubMed ID: 24196442
[TBL] [Abstract][Full Text] [Related]
40. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma.
Kondo T; Oue N; Yoshida K; Mitani Y; Naka K; Nakayama H; Yasui W
Cancer Res; 2004 Jan; 64(2):523-9. PubMed ID: 14744765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
